Dataset Information

Ena-DATASET-ICR-GM-02-06-2016-20:07:58:368-155 - samples

ABSTRACT: Samples were sequenced from 33 multiple myeloma patients including tumor presentation and relapse samples and a matched patient control sample. Tumor DNA was isolated from CD138-positive plasma cells. Control DNA originated from peripheral blood leukapheresis products collected after induction therapy. Libraries were prepared using the SureSelectQXT sample prep kit and the SureSelect Clinical Research Exome kit (Agilent), with additional baits covering the Ig and MYC loci. Paired-end sequencing was performed to an average sequencing depth of 118× on a HiSeq2500 (Illumina).

PROVIDER: EGAD00001002165 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Similar Datasets

Project description:in order to document molllecular signature of iMycCα B-cell lymphomas, RNA sequecing of CD138+ and CD138-B-cell lymphomas was performed and normalized expression data was obtained for all protein-coding genes Methods: B220+IgM+IgD+CD138+ and B220+IgM+IgD+CD138- B-cell lymphomas were investigated in the iMycCα mice. Total RNA from lymphoma cells (purified with B220-coupled beads from Miltenyi Biotech) was extracted and analysed by microarray (Génome et Transcriptome, GenoToul, Toulouse, France; get.genotoul.fr). RNA-seq paired-end libraries were prepared according to the Illumina protocol with some adjustments, using the TruSeq Stranded Total RNA Gold library prep Kit (Illumina, San Diego, USA). Libraries were quantified by qPCR using the KAPA Library Quantification Kit (Roche, Basel, Switzerland). Libraries quality was assessed by the HS NGS kit on the Fragment Analyzer (Agilent Technologies, Santa Clara, USA). Libraries were equimolarly pooled and RNA sequencing was then performed on one S4 lane of the Illumina NovaSeq 6000 instrument (Illumina, San Diego, USA), using the NovaSeq 6000 S4 v1.5 Reagent Kit (300 cycles), and a paired-end 2 x 150 pb strategy Results: Bioinformatic analysis defined CD138+ and CD138- B-cell lymphomas as two groups with a different transcriptome signature ( 2522 genes differentially expressed) driving various arrays of the immune responses and expressing different signaling/metabolic pathways. Enrichment of previously established human Burkitt lymphoma (BL) and multiple myeloma signatures was tested in our CD138+ B-cell lymphomas. In contrast to BL, myeloma up and down signatures were significantly enriched, emphasizing the molecular similarity of mouse CD138+ B-cell lymphomas to human multiple myeloma cells and the relevance of our mice as pertinent model of plasma B-cell lymphomas. Conclusions: Our mouse model carrying a homozygous insertion of c-myc into the IgH locus develops B-cell lymphoma with a large part of CD138+ plasma cell neoplasms. Its interesting and large transcriptome similarities with human myelomas make this mouse model an accurate, reliable experimental myeloma model.

Dataset Information

Ena-DATASET-ICR-GM-02-06-2016-20:07:58:368-155 - samples

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets